Top

BMC Cancer

Published in:

Open Access 01-12-2024 | Osteosarcoma | Research

Oridonin-induced ferroptosis and apoptosis: a dual approach to suppress the growth of osteosarcoma cells

Authors: Feifan Zhang, Yang Hao, Ning Yang, Man Liu, Yage Luo, Ying Zhang, Jian Zhou, Hongjian Liu, Jitian Li

Published in: BMC Cancer | Issue 1/2024

Abstract

Background

Osteosarcoma (OS) is one of the most common aggressive bone malignancy tumors in adolescents. With the application of new chemotherapy regimens, finding new and effective anti-OS drugs to coordinate program implementation is urgent for the patients of OS. Oridonin had been proved to mediate anti-tumor effect on OS cells, but its mechanism has not been fully elucidated.

Methods

The effects of oridonin on the viability, clonal formation and migration of 143B and U2OS cells were detected by CCK-8, colony formation assays and wound-healing test. Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis was used to explore the mechanism of oridonin on OS. Western blot (WB), real-time quantitative PCR (qRT-PCR) were used to detect the expression levels of apoptosis and ferroptosis-relative proteins and genes. Annexin V-FITC apoptosis detection kit and flow cytometry examination were used to detect the level of apoptosis. Iron assay kit was used to evaluate the relative Fe²⁺ content. The levels of mitochondrial membrane potential and lipid peroxidation production was determined by mitochondrial membrane potential detection kit and ROS assay kit.

Results

Oridonin could effectively inhibit the survival, clonal formation and metastasis of OS cells. The KEGG results indicated that oridonin is associated with the malignant phenotypic signaling pathways of proliferation, migration, and drug resistance in OS. Oridonin was capable of inhibiting expressions of BAX, cl-caspase3, SLC7A11, GPX4 and FTH1 proteins and mRNA, while promoting the expressions of Bcl-2 and ACSL4 in 143B and U2OS cells. Additionally, we found that oridonin could promote the accumulation of reactive oxygen species (ROS) and Fe²⁺ in OS cells, as well as reduce mitochondrial membrane potential, and these effects could be significantly reversed by the ferroptosis inhibitor ferrostatin-1 (Fer-1).

Conclusion

Oridonin can trigger apoptosis and ferroptosis collaboratively in OS cells, making it a promising and effective agent for OS therapy.

Available only for authorised users

Andersen GB, Knudsen A, Hager H, Hansen LL, Tost J. miRNA profiling identifies deregulated miRNAs associated with osteosarcoma development and time to metastasis in two large cohorts. Mol Oncol. 2018;12(1):114–31. https://doi.org/10.1002/1878-0261.12154.CrossRefPubMed

Ritter J, Bielack SS. Osteosarcoma. Ann Oncol. 2010;21(Suppl 7):vii320-5. https://doi.org/10.1093/annonc/mdq276.CrossRefPubMed

Gill J, Gorlick R. Advancing therapy for osteosarcoma. Nat Rev Clin Oncol. 2021;18(10):609–24. https://doi.org/10.1038/s41571-021-00519-8.CrossRefPubMed

Meltzer PS, Helman LJ. New horizons in the treatment of osteosarcoma. N Engl J Med. 2021;385(22):2066–76. https://doi.org/10.1056/NEJMra2103423.CrossRefPubMed

Bielack SS, Blattmann C, Borkhardt A, Csóka M, Hassenpflug W, Kabíčková E, et al. Osteosarcoma and causes of death: a report of 1520 deceased patients from the cooperative osteosarcoma study group (COSS). Eur J Cancer. 2022;176:50–7. https://doi.org/10.1016/j.ejca.2022.09.007.CrossRefPubMed

Li S, Liu F, Zheng K, Wang W, Qiu E, Pei Y, et al. CircDOCK1 promotes the tumorigenesis and cisplatin resistance of osteogenic sarcoma via the miR-339-3p/IGF1R axis. Mol Cancer. 2021;20(1):161. https://doi.org/10.1186/s12943-021-01453-0.CrossRefPubMedPubMedCentral

Zhang Y, Lou Y, Wang J, Yu C, Shen W. Research status and molecular mechanism of the traditional Chinese medicine and antitumor therapy combined strategy based on tumor microenvironment. Front Immunol. 2020;11:609705. https://doi.org/10.3389/fimmu.2020.609705.CrossRefPubMed

Zhang X, Qiu H, Li C, Cai P, Qi F. The positive role of traditional Chinese medicine as an adjunctive therapy for cancer. Biosci Trends. 2021;15(5):283–98. https://doi.org/10.5582/bst.2021.01318.CrossRefPubMed

Ma YC, Ke Y, Zi X, Zhao W, Shi XJ, Liu HM. Jaridonin, a novel ent-kaurene diterpenoid from Isodon rubescens, inducing apoptosis via production of reactive oxygen species in esophageal cancer cells. Curr Cancer Drug Targets. 2013;13(6):611–24. https://doi.org/10.2174/15680096113139990030.CrossRefPubMedPubMedCentral

10.

Li F, Fan J, Wu Z, Liu RY, Guo L, Dong Z, et al. Reversal effects of Rabdosia rubescens extract on multidrug resistance of MCF-7/Adr cells in vitro. Pharm Biol. 2013;51(9):1196–203. https://doi.org/10.3109/13880209.2013.784342.CrossRefPubMed

11.

Sartippour MR, Seeram NP, Heber D, Hardy M, Norris A, Lu Q, et al. Rabdosia rubescens inhibits breast cancer growth and angiogenesis. Int J Oncol. 2005;26(1):121–7.PubMed

12.

Kazantseva L, Becerra J, Santos-Ruiz L. Oridonin enhances antitumor effects of doxorubicin in human osteosarcoma cells. Pharmacol Rep. 2022;74(1):248–56. https://doi.org/10.1007/s43440-021-00324-1.CrossRefPubMed

13.

Kadota S, Basnet P, Ishii E, Tamura T, Namba T. Antibacterial activity of trichorabdal a from Rabdosia trichocarpa against helicobacter pylori. Zentralbl Bakteriol. 1997;286(1):63–7. https://doi.org/10.1016/s0934-8840(97)80076-x.CrossRefPubMed

14.

Du Y, Zhang J, Yan S, Tao Z, Wang C, Huang M, et al. Oridonin inhibits the proliferation, migration and invasion of human osteosarcoma cells via suppression of matrix metalloproteinase expression and STAT3 signalling pathway. J BUON. 2019;24(3):1175–80.PubMed

15.

Liu Y, Liu YZ, Zhang RX, Wang X, Meng ZJ, Huang J, et al. Oridonin inhibits the proliferation of human osteosarcoma cells by suppressing Wnt/β-catenin signaling. Int J Oncol. 2014;45(2):795–803. https://doi.org/10.3892/ijo.2014.2456.CrossRefPubMed

16.

Zhu X, Li S. Ferroptosis, necroptosis, and Pyroptosis in gastrointestinal cancers: the chief culprits of tumor progression and drug resistance. Adv Sci (Weinh). 2023;10(26):e2300824. https://doi.org/10.1002/advs.202300824.CrossRefPubMed

17.

Schmitt CA. Senescence, apoptosis and therapy--cutting the lifelines of cancer. Nat Rev Cancer 2003;3(4):286–295. https://doi.org/10.1038/nrc1044.

18.

Nössing C, Ryan KM. 50 years on and still very much alive: 'Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics'. Br J Cancer. 2023;128(3):426–31. https://doi.org/10.1038/s41416-022-02020-0.CrossRefPubMed

19.

Cabanos HF, Hata AN. Emerging insights into targeted therapy-tolerant Persister cells in Cancer. Cancers (Basel). 2021;13(11):2666. https://doi.org/10.3390/cancers13112666.CrossRefPubMed

20.

Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22(4):266–82. https://doi.org/10.1038/s41580-020-00324-8.CrossRefPubMedPubMedCentral

21.

Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–72. https://doi.org/10.1016/j.cell.2012.03.042.CrossRefPubMedPubMedCentral

22.

Liu X, Du S, Wang S, Ye K. Ferroptosis in osteosarcoma: a promising future. Front Oncol. 2022;12:1031779. https://doi.org/10.3389/fonc.2022.1031779.CrossRefPubMedPubMedCentral

23.

Zhang C, Liu X, Jin S, Chen Y, Guo R. Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. Mol Cancer. 2022;21(1):47. https://doi.org/10.1186/s12943-022-01530-y.CrossRefPubMedPubMedCentral

24.

Friedmann Angeli JP, Krysko DV, Conrad M. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nat Rev Cancer. 2019;19(7):405–14. https://doi.org/10.1038/s41568-019-0149-1.CrossRefPubMed

25.

Su Y, Zhao B, Zhou L, Zhang Z, Shen Y, Lv H, et al. Ferroptosis, a novel pharmacological mechanism of anti-cancer drugs. Cancer Lett. 2020;483:127–36. https://doi.org/10.1016/j.canlet.2020.02.015.CrossRefPubMed

26.

Chen Q, Cao Y, Li H, Liu H, Liu Y, Bi L, et al. Sodium nitroprusside alleviates nanoplastics-induced developmental toxicity by suppressing apoptosis, ferroptosis and inflammation. J Environ Manag. 2023;345:118702. https://doi.org/10.1016/j.jenvman.2023.118702.CrossRef

27.

Yu H, Li JM, Deng K, Zhou W, Li KH, Wang CX, et al. GPX4 inhibition synergistically boosts mitochondria targeting nanoartemisinin-induced apoptosis/ferroptosis combination cancer therapy. Biomater Sci. 2023;11(17):5831–45. https://doi.org/10.1039/d3bm00601h.CrossRefPubMed

28.

Fu J, Li T, Yang Y, Jiang L, Wang W, Fu L, et al. Activatable nanomedicine for overcoming hypoxia-induced resistance to chemotherapy and inhibiting tumor growth by inducing collaborative apoptosis and ferroptosis in solid tumors. Biomaterials. 2021;268:120537. https://doi.org/10.1016/j.biomaterials.2020.120537.CrossRefPubMed

29.

Wang Y, Zhang L, Zhao G, Zhang Y, Zhan F, Chen Z, et al. Homologous targeting nanoparticles for enhanced PDT against osteosarcoma HOS cells and the related molecular mechanisms. J Nanobiotechnology. 2022;20(1):83. https://doi.org/10.1186/s12951-021-01201-y.CrossRefPubMedPubMedCentral

30.

He C, Jiang Y, Guo Y, Wu Z. Amplified Ferroptosis and apoptosis facilitated by differentiation therapy efficiently suppress the progression of osteosarcoma. Small. 2023:e2302575. https://doi.org/10.1002/smll.202302575.

31.

He T, Lin X, Yang C, Chen Z, Wang L, Li Q, et al. Theaflavin-3,3′-Digallate plays a ROS-mediated dual role in Ferroptosis and apoptosis via the MAPK pathway in human osteosarcoma cell lines and xenografts. Oxidative Med Cell Longev. 2022;2022:8966368. https://doi.org/10.1155/2022/8966368.CrossRef

32.

Miotto G, Rossetto M, Di Paolo ML, Orian L, Venerando R, Roveri A, et al. Insight into the mechanism of ferroptosis inhibition by ferrostatin-1. Redox Biol. 2020;28:101328. https://doi.org/10.1016/j.redox.2019.101328.CrossRefPubMed

33.

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25(4):402–8. https://doi.org/10.1006/meth.2001.1262.CrossRefPubMed

34.

Wang W, Green M, Choi JE, Gijón M, Kennedy PD, Johnson JK, et al. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569(7755):270–4. https://doi.org/10.1038/s41586-019-1170-y.CrossRefPubMedPubMedCentral

35.

Jiang Z, Lim SO, Yan M, Hsu JL, Yao J, Wei Y, et al. TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. J Clin Invest. 2021;131(8):e139434. https://doi.org/10.1172/JCI139434.CrossRefPubMedPubMedCentral

36.

Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol. 2015;33(27):3029–35. https://doi.org/10.1200/JCO.2014.59.4895.CrossRefPubMedPubMedCentral

37.

Pakos EE, Nearchou AD, Grimer RJ, Koumoullis HD, Abudu A, Bramer JA, et al. Prognostic factors and outcomes for osteosarcoma: an international collaboration. Eur J Cancer. 2009;45(13):2367–75. https://doi.org/10.1016/j.ejca.2009.03.005.CrossRefPubMed

38.

Tang JL, Liu BY, Ma KW. Traditional Chinese medicine. Lancet. 2008;372(9654):1938–40. https://doi.org/10.1016/S0140-6736(08)61354-9.CrossRefPubMed

39.

Cai M, Yao Y, Yin D, Zhu R, Fu T, Kong J, et al. Enhanced lysosomal escape of cell penetrating peptide-functionalized metal-organic frameworks for co-delivery of survivin siRNA and oridonin. J Colloid Interface Sci. 2023;646:370–80. https://doi.org/10.1016/j.jcis.2023.04.126.CrossRefPubMed

40.

Hwang TL, Chang CH. Oridonin enhances cytotoxic activity of natural killer cells against lung cancer. Int Immunopharmacol. 2023;122:110669. https://doi.org/10.1016/j.intimp.2023.110669.CrossRefPubMed

41.

Zhou F, Gao H, Shang L, Li J, Zhang M, Wang S, et al. Oridonin promotes endoplasmic reticulum stress via TP53-repressed TCF4 transactivation in colorectal cancer. J Exp Clin Cancer Res. 2023;42(1):150. https://doi.org/10.1186/s13046-023-02702-4.CrossRefPubMedPubMedCentral

42.

Zhang X, Feng H, Li Z, Guo J, Li M. Aspirin is involved in the cell cycle arrest, apoptosis, cell migration, and invasion of Oral squamous cell carcinoma. Int J Mol Sci. 2018;19(7):2029. https://doi.org/10.3390/ijms19072029.CrossRefPubMedPubMedCentral

43.

Poornima P, Kumar JD, Zhao Q, Blunder M, Efferth T. Network pharmacology of cancer: from understanding of complex interactomes to the design of multi-target specific therapeutics from nature. Pharmacol Res. 2016;111:290–302. https://doi.org/10.1016/j.phrs.2016.06.018.CrossRefPubMed

44.

Sun Y, Jiang X, Lu Y, Zhu J, Yu L, Ma B, et al. Oridonin prevents epithelial-mesenchymal transition and TGF-β1-induced epithelial-mesenchymal transition by inhibiting TGF-β1/Smad2/3 in osteosarcoma. Chem Biol Interact. 2018;296:57–64. https://doi.org/10.1016/j.cbi.2018.09.013.CrossRefPubMed

45.

Wang XH, Zhang SF, Bao JT, Liu FY. Oridonin synergizes with Nutlin-3 in osteosarcoma cells by modulating the levels of multiple Bcl-2 family proteins. Tumour Biol. 2017;39(6):1010428317701638. https://doi.org/10.1177/1010428317701638.CrossRefPubMed

46.

Jin S, Shen JN, Wang J, Huang G, Zhou JG. Oridonin induced apoptosis through Akt and MAPKs signaling pathways in human osteosarcoma cells. Cancer Biol Ther. 2007;6(2):261–8. https://doi.org/10.4161/cbt.6.2.3621.CrossRefPubMed

47.

Xu J, Li Y, Kang M, Chang C, Wei H, Zhang C, et al. Multiple forms of cell death: a focus on the PI3K/AKT pathway. J Cell Physiol. 2023;238(9):2026–38. https://doi.org/10.1002/jcp.31087.CrossRefPubMed

48.

Zhang J, Wang N, Zhou Y, Wang K, Sun Y, Yan H, et al. Oridonin induces ferroptosis by inhibiting gamma-glutamyl cycle in TE1 cells. Phytother Res. 2021;35(1):494–503. https://doi.org/10.1002/ptr.6829.CrossRefPubMed

49.

Wang W, Zhang N. Oridonin inhibits Hela cell proliferation via downregulation of glutathione metabolism: a new insight from metabolomics. J Pharm Pharmacol. 2023;75(6):837–45. https://doi.org/10.1093/jpp/rgad025.MathSciNetCrossRefPubMed

50.

Ouyang S, Li H, Lou L, Huang Q, Zhang Z, Mo J, et al. Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer. Redox Biol. 2022;52:102317. https://doi.org/10.1016/j.redox.2022.102317.CrossRefPubMedPubMedCentral

51.

Zhang T, Sun B, Zhong C, Xu K, Wang Z, Hofman P, et al. Targeting histone deacetylase enhances the therapeutic effect of Erastin-induced ferroptosis in EGFR-activating mutant lung adenocarcinoma. Transl lung. Cancer Res. 2021;10(4):1857–72. https://doi.org/10.21037/tlcr-21-303.CrossRef

52.

Feng Y, Huang J, Wang F, Lin Z, Luo H, Li Q, et al. Methylcrotonyl-CoA carboxylase subunit 1 (MCCA) regulates multidrug resistance in multiple myeloma. Life Sci. 2023;333:122157. https://doi.org/10.1016/j.lfs.2023.122157.CrossRefPubMed

53.

Zeng Y, Jiang H, Zhang X, Xu J, Wu X, Xu Q, et al. Canagliflozin reduces chemoresistance in hepatocellular carcinoma through PKM2-c-Myc complex-mediated glutamine starvation. Free Radic Biol Med. 2023;208:571–86. https://doi.org/10.1016/j.freeradbiomed.2023.09.006.CrossRefPubMed

54.

Qu S, Qi S, Zhang H, Li Z, Wang K, Zhu T, et al. Albumin-bound paclitaxel augment temozolomide treatment sensitivity of glioblastoma cells by disrupting DNA damage repair and promoting ferroptosis. J Exp Clin Cancer Res. 2023;42(1):285. https://doi.org/10.1186/s13046-023-02843-6.CrossRefPubMedPubMedCentral

55.

Wang JG, Li DL, Fan R, Yan MJ. Zerumbone combined with gefitinib alleviates lung cancer cell growth through the AKT/STAT3/SLC7A11 axis. Neoplasma. 2023;70(1):58–70. https://doi.org/10.4149/neo_2022_220418N423.CrossRefPubMed

Title: Oridonin-induced ferroptosis and apoptosis: a dual approach to suppress the growth of osteosarcoma cells
Authors: Feifan Zhang
Yang Hao
Ning Yang
Man Liu
Yage Luo
Ying Zhang
Jian Zhou
Hongjian Liu
Jitian Li
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Osteosarcoma
osteosarcoma
Published in: BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-024-11951-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

Radiogenomic analysis of ultrasound phenotypic features coupled to proteomes predicts metastatic risk in primary prostate cancer

Diabetes and the social, biologic, and behavioral determinants of endometrial cancer in the United States

Circulating miR-16-5p, miR-92a-3p and miR-451a are biomarkers of lung cancer in Tunisian patients

Astragaloside IV-PESV inhibits prostate cancer tumor growth by restoring gut microbiota and microbial metabolic homeostasis via the AGE-RAGE pathway

Nomogram incorporating prognostic immune-inflammatory-nutritional score for survival prediction in pancreatic cancer: a retrospective study

Prognostic value of pre-treatment [18F] FDG PET/CT in recurrent nasopharyngeal carcinoma without distant metastasis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer